In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. Extra contributors will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will probably be presented as "insert-on" therapy. In Phase https://abbv-744-in-acute-myeloid36891.ampedpages.com/top-brd4-inhibition-by-abbv-744-in-cancer-research-studies-secrets-59225268